ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$151.01|
|52 Week High||US$175.91|
|52 Week Low||US$105.56|
|1 Month Change||-4.74%|
|3 Month Change||4.85%|
|1 Year Change||30.05%|
|3 Year Change||88.62%|
|5 Year Change||128.60%|
|Change since IPO||331.46%|
Recent News & Updates
AbbVie: Buy, Hold, Or Sell After Q1 Results?
AbbVie is a very high-quality company with strong cash flows, exactly the type of company you want to own if we fall into a recession. But it recently posted disappointing results that caused a selloff. Despite near-term pain, the long-term thesis remains strong.
|ABBV||US Biotechs||US Market|
Return vs Industry: ABBV exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: ABBV exceeded the US Market which returned -12.9% over the past year.
|ABBV Average Weekly Movement||3.6%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: ABBV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ABBV's weekly volatility (4%) has been stable over the past year.
About the Company
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.
AbbVie Fundamentals Summary
|ABBV fundamental statistics|
Is ABBV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABBV income statement (TTM)|
|Cost of Revenue||US$17.14b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||7.02|
|Net Profit Margin||21.87%|
How did ABBV perform over the long term?See historical performance and comparison
3.7%Current Dividend Yield
Is AbbVie undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ABBV ($151.01) is trading below our estimate of fair value ($341.33)
Significantly Below Fair Value: ABBV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ABBV is poor value based on its PE Ratio (21.5x) compared to the US Biotechs industry average (15.1x).
PE vs Market: ABBV is poor value based on its PE Ratio (21.5x) compared to the US market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: ABBV's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ABBV is overvalued based on its PB Ratio (16.4x) compared to the US Biotechs industry average (1.5x).
How is AbbVie forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABBV's earnings are forecast to decline over the next 3 years (-0.3% per year).
Earnings vs Market: ABBV's earnings are forecast to decline over the next 3 years (-0.3% per year).
High Growth Earnings: ABBV's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ABBV's revenue (0.7% per year) is forecast to grow slower than the US market (7.8% per year).
High Growth Revenue: ABBV's revenue (0.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABBV's Return on Equity is forecast to be very high in 3 years time (82.3%).
How has AbbVie performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABBV has a large one-off loss of $3.7B impacting its March 31 2022 financial results.
Growing Profit Margin: ABBV's current net profit margins (21.9%) are higher than last year (10.1%).
Past Earnings Growth Analysis
Earnings Trend: ABBV's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: ABBV's earnings growth over the past year (144%) exceeds its 5-year average (9% per year).
Earnings vs Industry: ABBV earnings growth over the past year (144%) exceeded the Biotechs industry 96.9%.
Return on Equity
High ROE: Whilst ABBV's Return on Equity (76.54%) is outstanding, this metric is skewed due to their high level of debt.
How is AbbVie's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ABBV's short term assets ($26.5B) do not cover its short term liabilities ($32.5B).
Long Term Liabilities: ABBV's short term assets ($26.5B) do not cover its long term liabilities ($94.4B).
Debt to Equity History and Analysis
Debt Level: ABBV's net debt to equity ratio (405%) is considered high.
Reducing Debt: ABBV's debt to equity ratio has reduced from 744.8% to 451.4% over the past 5 years.
Debt Coverage: ABBV's debt is well covered by operating cash flow (31%).
Interest Coverage: ABBV's interest payments on its debt are well covered by EBIT (8.7x coverage).
What is AbbVie current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ABBV's dividend (3.73%) is higher than the bottom 25% of dividend payers in the US market (1.58%).
High Dividend: ABBV's dividend (3.73%) is low compared to the top 25% of dividend payers in the US market (4.11%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, ABBV has been paying a dividend for less than 10 years.
Growing Dividend: ABBV's dividend payments have increased, but the company has only paid a dividend for 9 years.
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (77.3%), ABBV's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (45.2%), ABBV's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Gonzalez (67 yo)
Mr. Richard A. Gonzalez, also known as Rick, serves as the Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD23.91M) is above average for companies of similar size in the US market ($USD13.34M).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
Experienced Management: ABBV's management team is considered experienced (3.5 years average tenure).
Experienced Board: ABBV's board of directors are considered experienced (9.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AbbVie Inc.'s employee growth, exchange listings and data sources
- Name: AbbVie Inc.
- Ticker: ABBV
- Exchange: NYSE
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$266.851b
- Shares outstanding: 1.77b
- Website: https://www.abbvie.com
Number of Employees
- AbbVie Inc.
- 1 North Waukegan Road
- North Chicago
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.